Sexually Transmitted Infections

Assessing the costs and outcomes of control programmes for sexually transmitted infections: a systematic review of economic evaluations

Journal:	*Sexually Transmitted Infections*
Manuscript ID	Draft
Article Type:	Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Bloch, Sonja; University of Birmingham, Health Economics Unit, Institute of Applied Health Research Jackson, Louise; University of Birmingham, Health Economics Unit, Institute of Applied Health Research Frew, Emma; University of Birmingham, Health Economics Unit, Institute of Applied Health Research Ross, Jonathan; University Hospitals Birmingham NHS Foundation Trust, Whittall Street Clinic
Keywords:	Economics, Medical, Diagnostic Screening Programs, SEXUAL HEALTH, INFECTION CONTROL, HIV

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Assessing the costs and outcomes of control programmes for sexually transmitted infections: a systematic review of economic evaluations

Sonja C. M. Bloch MSc [1], Louise J. Jackson PhD [1], Emma Frew PhD[1], Jonathan D. C. Ross MBChB MD FRCP [2]

[1] Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, UK

[2] Whittall Street Clinic, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Address correspondence to

Sonja Bloch

Health Economics Unit, University of Birmingham, Birmingham, West Midlands, B15 2TT, UK

s.bloch@pgr.bham.ac.uk

This research was part of the corresponding author's PhD research which was funded by Umbrella Sexual Health Services, University Hospital Birmingham NHS Foundation Trust. The funder played no role in the design of the study, nor the analysis of the data, nor in the preparation of the manuscript.

SB undertook the main analysis and prepared the initial manuscript. All other authors (LJ, JR, EF) contributed to the analysis and the development of the manuscript. All authors approved the final version. LJ is the guarantor of this review.

Keywords: economic evaluation, control, testing, screening, sexually transmitted infections, STIs, HIV

Word count: 2,964

ABSTRACT

Objective: To identify economic evaluations of interventions to control sexually transmitted infections (STIs) and HIV targeting young people, and to assess how costs and outcomes are measured in these studies.

Design: Systematic review.

Data sources: Seven databases were searched (Medline (Ovid), EMBASE (Ovid), Web of Science, PsycINFO, NHS EED, NHS HTA, and DARE) from January 1999 to April 2019. Key search terms were STIs (chlamydia, gonorrhoea, syphilis) and HIV, cost benefit, cost utility, economic evaluation, public health, screening, testing, and control.

Review methods: Studies were included that measured costs and outcomes to inform an economic evaluation of any programme to control STIs and HIV targeting individuals predominantly below 30 years of age at risk of, or affected by, one or multiple STIs and/or HIV in OECD countries. Data was extracted and tabulated and included study results and characteristics of economic evaluations. Study quality was assessed using the Philips and BMJ checklists. Results were synthesised narratively.

Results: 9,530 records were screened and categorised. Of these, 31 were included for data extraction and critical appraisal. The majority of studies assessed the cost-effectiveness or cost-utility of screening interventions for chlamydia from a provider perspective. The main outcome measures were major outcomes averted and quality-adjusted life years. Studies evaluated direct medical costs, e.g. programme costs and eleven included indirect costs, such as productivity losses. The study designs were predominantly model-based with significant heterogeneity between the models.

Discussion/Conclusion: None of the economic evaluations encompassed aspects of equity or context, which are highly relevant to sexual health decision-makers. The review demonstrated heterogeneity in approaches to evaluate costs and outcomes for STI/HIV control programmes. The low quality of available studies along with the limited focus, i.e. almost all studies relate to chlamydia, highlight the need for high-quality economic evaluations to inform the commissioning of sexual health services.

BACKGROUND

Economic evaluations of public health interventions are complex in nature but essential to support efficient allocation of healthcare spending and the optimal commissioning of clinical services. One reason for this complexity is that public health interventions encompass aims beyond just health such as equity and educational outcomes.[1-5] In contrast to healthcare interventions, public health interventions are often implemented in complex settings where there are multi-sectoral costs and outcomes. Methodological guidance for economic evaluations in public health emphasises the importance of considering factors, such as: local decision-making processes; longer time horizons; broader costs and outcomes;[1,6,7] and adopting a societal perspective to include health and non-health costs and effects; as well as utilising different economic evaluation designs, depending on the needs of decision-makers.[6,7] This contrasts to 'standard' economic evaluations where these aspects would not usually be taken into account.[8,9] Improving sexual health and the control of sexually transmitted infections (STIs) and human immunodeficiency virus (HIV) is an important dimension of public health. STI and HIV control encompasses treatment, screening, and testing, which aims to reduce the incidence and prevalence of infections.[10]

Very few systematic reviews of economic evidence in sexual health have been conducted.[11,12] Initial scoping showed that there is a small existing base of robust evidence to inform economic evaluations in relation to the outcomes of STI and HIV screening programmes as well as assessing new modes of delivery in a sexual health context. This includes economic evaluations for the delivery of online sexual health services and services provided in community settings, such as in pharmacies.[11,13,14]

The aim of this systematic review was to identify economic evaluations of STI and HIV control programmes targeting young people (under 30 years) and to assess how costs and outcomes are measured, valued, and analysed.

METHODS

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the methods outlined in the University of York Centre for Review and Dissemination (CRD) guidelines.[15,16]

The search strategy involved three main search areas – STIs, economic evaluations, and public health. The STIs (chlamydia, gonorrhoea, syphilis) and HIV were chosen as a focus because they are the STIs most commonly tested and screened for in the United Kingdom (UK).[17,18]

Seven databases were searched (MEDLINE, EMBASE, Web of Science, PsycINFO, NHS Economic Evaluation Database [EED], NHS Health Technology Assessment [HTA], and the Database of Abstracts of Reviews of Effects [DARE]). In addition, the UK National Institute of Health and Care Excellence (NICE) was searched. The initial search strategy was developed for MEDLINE database. MeSH terms, truncation, and wild card symbols were adapted accordingly for the other databases. An example of the search strategy applied to the MEDLINE database can be found in Supplement 1.

The search results were limited to the period January 1999 to April 2019 and to studies involving 'humans' only. The timeframe was selected due to the establishment of NICE in 1999 alongside guidelines for the conduct of economic evaluation, termed the 'reference case'.[19,20]

Inclusion criteria

Studies were included if they met the following criteria: the study population consisted of women and/or men predominantly below 30 years of age who were at risk of or affected by one of the specified STIs (chlamydia, gonorrhoea, syphilis) or HIV and living in OECD countries; the focus was any intervention or programme to control STIs or HIV; and costs and outcomes were measured to inform an economic evaluation (see Supplement 2). Publication in all languages was included.

Selection of papers for review

For management and categorisation of the references, EndNote referencing manager (version X9) was utilised.[21] For the systematic selection of studies, the strategy recommended by the CRD, University of York was applied. The records identified through the search strategy were categorised using a two-stage process as suggested by Roberts et al.[22] The first stage included categories from A to I and the second stage further categorised studies identified as A and B, which were then assigned to categories 1 to 5 (see Figure 1). The identification and initial categorisation was performed by one author (SB) and two authors (LJ, EF) checked the selection process (screening, eligibility, and inclusion) to confirm the categorisation of studies. The final papers selected were studies that presented a complete economic evaluation

Data synthesis

The data was tabulated and synthesised narratively. For a list of data extraction categories see Supplement 2. This method of synthesis was chosen due to the diversity of studies found and is based on the narrative synthesis framework from the CRD of the University of

York.[16,23] Based on the generated tables, the different studies were compared in a textual form. In combination with the quality assessment, it was then possible to appraise the robustness of evidence for studies conducting economic evaluations of STI/HIV control programmes.

Quality assessment

The quality of included studies was assessed by applying the BMJ checklist for reviewing economic evaluations.[24] For modelling studies, the Philips criteria were utilised.[25] The purpose of the quality assessment was to critically appraise the methodological characteristics of current economic evidence for STI and HIV control programmes rather than to exclude studies. The findings of the quality assessment were used to inform the main discussion of the results, instead of being reported separately.

RESULTS

The PRISMA diagram shows the different stages of the systematic review process (see Figure 1). A total of 9,522 records were obtained from the databases and an additional eight were found through initial hand searching. After removing 3,485 duplicates, 433 records were screened as part of Stage I based on title, abstract, and keywords (see Supplement 3 for details of the categories used). This resulted in 64 records being considered for Stage II categorisation with two additional records identified from hand searching of reference lists. The assessment of full-texts resulted in 31 category A(1) studies identified for inclusion in the quality assessment and narrative synthesis.

Study characteristics

Table 1 provides an overview of the main characteristics of the 31 studies identified for inclusion. The main countries where the studies took place were the Netherlands (7)[26-32], UK (8)[33-40], and United States of America (12). The majority of studies compared the cost-effectiveness or cost-utility of two or more different screening options for chlamydia (25 studies). Six studies included gonorrhoea screening in their strategy[33,41-45] and one focussed on the cost-effectiveness of age-specific HIV screening.[46] The search did not identify any study assessing interventions for syphilis. Two studies considered newer screening modes, such as pharmacy based screening[29] and internet-based testing.[47]

Study populations

The majority of studies (19) focussed on both men and women aged up to 30 years as the study population. Eleven interventions looked at women only, and the study by Jackson et al.

was the only study that exclusively focused on the cost-effectiveness of screening men for STIs.[33]

Study findings

The general conclusion in 16 of 28 studies was that screening for chlamydia below the age of 30 years is likely to be cost-effective. Nine economic evaluations concluded that screening for chlamydia was likely to be cost-effective if certain assumptions, such as uptake rate and chlamydia prevalence were correct.[29,31,32,34,35,38,48-50] However, other studies have highlighted uncertainties about these assumptions. For example, one of the more recent studies used a much lower uptake rate for the screening programmes because the authors considered the rates used in previous studies to be too optimistic.[26] Four additional studies did not find the STI intervention to be cost-effective.[30,36,44,51] The cost-consequence analysis by Jackson et al. found that costs and outcomes were similar across the assessed interventions.[33]

Table 1. Characteristics of economic evaluations of control programmes for STIs

Author (year)	*Country*	*Study aims and context*	*STIs*			*Target population*	*Intervention was found to be cost-effective*	*Main CE results*
			CT	*NG*	*HIV*		*(✓,X,✓/X,NA)*	
Neilan (2018)	USA	Identify the optimal age for one-time HIV screening for adolescents and young adults			✓	Adolescents and young adults 13-24 years without identified risk factors	✓	ICER = $96,000/YLS (cost-effective by U.S. standards: less than $100,000/YLS)
Owusu-Edusei (2016)	USA	Explore the CE of a patient-directed, universal, opportunistic *CT* Opt-Out Testing strategy for all women aged 15-24 years	✓			High risk women 15-24 years	✓	ICER estimated range from cost-saving to $19,974/QALY saved
de Wit (2015)	NL	Evaluate the CE of repeated CT screening and its influence on incidence and prevalence	✓			16-29 year old men and women	X	More than 5,000€/MOA; Minimum 50,000€/QALY
Jackson (2015)	UK	Compare costs and outcomes of two STI screening interventions targeted at men in football club settings in England, including screening promoted by team captains	✓	✓		Men (18 years and over) within six amateur football clubs in London	NA	Average cost: £82, £88, £89 per intervention
Teng (2015)	USA	Incorporate the age dependency of the infection risk into an economic study of CT screening; Optimise age-dependent screening strategies	✓			14-25 year old women; intercity cohort	✓	Considering age-dependency is cost-saving
Gillespie (2012)	IRE	Estimate the cost and CE of opportunistic CT screening	✓			18-29 years	X	ICER/MOA=6,093€ and ICER/QALY=94,717€
Huang (2011)	USA	Model a hypothetical cohort of 10,000 women/year who order an internet-based CT screening kit	✓			Women (no defined age)	✓	36 cases of PID prevented; $41,000 saved (direct medical costs)
Turner (2011)	UK	Compare the cost, CE, and sex equity of different intervention strategies within the English NCSP	✓			Individuals eligible for the NCSP (15-24 years); women & men	✓/X	Increasing male screening to 24%=£528 costs per infection treated; PN efficacy to 0.8=£449 costs per infection diagnosed
de Vries (2008)	NL	Estimate the CE of repeated screening for CT at various time intervals	✓			Heterosexual men and women; (15-29 years)	✓	ICER: below 20,000€ (Dutch threshold) for interval strategies for CT screening
Gift (2008)	USA	Examine the impact on men and their female partners of screening men for CT	✓			Women and men 15-24 years; equal distribution of gender	✓	$10,520/QALY saved over expanded screening of women
Adams (2007)	UK	Estimate the CE of the NCSP and its alternatives in England	✓			Men and women under 25 years	✓/X	Average CE ratio is about £27,000
Low (2007)	UK	Examine the CE of active CT screening approaches in preventing major clinical outcomes	✓			Women and men (12-62 years), 50% women	X	ICER for women screening only = 28,000 £/MOA; ICER for screening men and women = 25,700 £/MOA
Andersen (2006)	DK	Estimate the incremental effects and costs of home sampling screening for CT over the current in-office screening practice	✓			Strategy implemented among men and women 15-24 years	✓/X	Direct costs: ICER = $292; Societal costs were total costs/MOA= $3,186; from year 3 the programme was cost-saving
Bernstein (2006)	USA	Identify an optimal screening algorithm for NG infection among women in private sector care		✓		Hypothetical population of women (15-35 years); mixed race/ethnicity; 15% drug users	✓	No screening was cost-saving over all screening strategies; Screening at risk women under 25 years is most cost-effective
de Vries (2006)	NL	Estimate the impact of a screening programme on CT incidence and prevalence in the population	✓			Men and women (15-29 years)	✓	Net costs/MOA=73€
Evenden (2006)	UK	Model the dynamics of infection recovery and sequelae to quantify CE of various CT screening strategies	✓			No details on target population; aim was to identify high risk groups	✓	£1,500/month saved when high-risk person screened; £200/month saved when low-risk person screened
Walleser (2006)	AU	Examine the CE of a hypothetical screening programme for CT based on annual opportunistic testing of women consulting a GP	✓			Women 25 years or younger consulting a GP	✓	Cost/QALY=$2,968
Aledort (2005)	USA	Assess the CE of screening women for NG seeking care in urban EDs using two different testing devices		✓		Women (15-29 years); sexually active; presenting to the ED with non-genitourinary symptoms	✓	ICER=$6,490/QALY
Evenden (2005)	UK	Capture CT infection dynamics within a population, incorporating the behaviour of different risk groups, and provide a cost-benefit study for screening	✓			Men and women (16-24 years)	✓/X	5% high-risk group screening=£1,500 saved/person screened; 1% screening=£200 saved/person screened
Gift (2005)	USA	Conduct a CEA of five interventions to encourage public STI clinic patients infected with CT/NG to return for re-screening	✓	✓		Men and women (14-30 years) diagnosed with and treated for CT/NG in two STI clinics	✓	$622/infection treated (programme perspective); $813/infection treated (societal perspective)

Table 1. Characteristics of economic evaluations of control programmes for STIs

Author (year)	*Country*	*Study aims and context*	*STIs*			*Target population*	*Intervention was found to be cost-effective*	*Main CE results*
			CT	*NG*	*HIV*		*(✓,X,✓/X,NA)*	
Hu (2004)	USA	Assess the CE of new strategies for CT screening	✓			Sexually active women (15-29 years)	✓	$2,350 to $7,490 cost/QALY
Norman (2004)	UK	Determine CE of screening for CT in two different clinics	✓			Women; up to 20 years; 20-24 years; 25-29 years; 30 and above; Aberdeen and Glasgow	✓	Net cost £771.36/MOA
Novak (2004)	SE	Assess the CE of identifying and treating asymptomatic carriers of CT	✓			Women and men (20-24 years) in Umea, Sweden	✓/X	Cost per prevented male CT case is $5,758
Tao (2004)	USA	Evaluate a mixed-integer programme to model CT in women visiting publicly funded family planning clinics aiming to maximise number of infected women cured of CT	✓			Women below 20 years, 20-24 years and above 24 years	✓/X	Re-screening: number of cases cured 89-283; cost savings $61,779-$166,779; Rescreening vs. no re-screening; Additional cases cure 7-20; Additional cost savings $3,088-$16,820
van Bergen (2004)	NL	Assess the effectiveness and CE of a pharmacy-based screening programme for CT in a high-risk health centre population in Amsterdam using mailed home collected urine samples	✓			Women aged 14-29 years; multicultural, lower income area in Amsterdam; 50% of population had a Surinamese/ Antillean background	✓/X	Cost-saving to 3,872€/PID case averted
Gift (2002)	USA	Examine the CE of routine dual treatment of women with NG infection with or without separate testing for CT and restricting treatment for CT to women testing positive for CT	✓	✓		Asymptomatic women infected with NG	X	-$130 (cost saving) to $557 cost/ PID case averted
Mehta (2002)	USA	Evaluate the CE of enhanced screening for NG and CT in an ED setting	✓	✓		Men and women (18-31 years)	✓	-$437 (cost saving) to $1694 per case treated
van Valkengoed (2001)	NL	Evaluate the CE of a systematic screening programme for asymptomatic CT infections	✓			Women aged 15-40 years	X	Net cost $15,800/MOA
Postma (2000)	NL	Estimate the CE of screening women for asymptomatic infection with CT in general practice	✓			Men and women below the age of 30; different age sub-groups	✓/X	$386/MOA for women aged 20-24 $644/MOA for women aged 25-29 $2,583/MOA for women aged 30-34
Townshend (2000)	UK	Evaluate impacts of a variety of screening interventions with a focus on the incidence of sequelae of CT	✓			Population was divided into risk groups (two for women three for men) and age groups (12±15, 16±20, 21±25, 26±40 years)	✓	Intervention is cost-saving; After 5 years around 30,000 PIDs, 7,000 infertility and 700 cases of ectopic pregnancies would be prevented per year
Welte (2000)	NL	Develop a novel dynamic approach for the economic evaluation of CT prevention measures; determine the CE of a general practice-based screening programme	✓			Men and women (15-64 years)	✓/X	-$492/MOA for direct costs; -$1,086/MOA including indirect costs

✓=Done, ✓/X = To some extent completed, X=Not reported; NA = Not applicable
ART=Anti-retroviral treatment; AYA=Adolescents and young adults; CDC=Center for Disease Control; CE=cost-effectiveness; CEA=cost-effectiveness analysis; CEAC=cost-effectiveness acceptability curve; CT=*Chlamydia trachomatis*; ED=Emergency department; GP=general practitioner; HIV=Human immunodeficiency virus; ICER=Incremental cost-effectiveness ratio; MO= Major outcome; MOA=Major outcome averted; NCSP=National Chlamydia Screening Programme; NG=*Neisseria gonorrhoeae*; PID=Pelvic inflammatory disease; QALY=Quality-adjusted life years; RIS=rapid immunochromotographic strip test; SA=Sensitivity analysis, YLS=Years of Life Saved
Country abbreviations: AU=Australia; DK=Denmark; IRE=Ireland; NL=Netherlands; SE=Sweden; UK=United Kingdom; USA=United States of America

Methodological considerations

Types of economic evaluations

The predominant method of economic evaluation applied was cost-effectiveness analysis (20 studies) followed by cost-utility analysis (8 studies)[26,27,35,41,51-54]. The latter measures outcomes in quality-adjusted life years (QALYs) whereas a cost-effectiveness analysis assesses outcomes in natural units, i.e. life years gained or major outcome averted, which in this context often refers to pelvic inflammatory disease (PID) or infertility. One study self-identified as a cost-benefit analysis where costs and consequences are expressed in monetary units.[23,38] The studies by Jackson et al. and Tao et al. conducted cost-consequence analyses.[33,50] Cost-consequence analyses list all costs and a catalogue of different outcomes of alternatives are listed separately, which results in no definite cost-outcome ratio.[55] Across the 20 years considered within this review, cost-utility analyses were more frequently applied from the year 2005 onwards (see Table 2).

Outcome measures

With respect to outcome measures, 16 out of the 31 studies applied major outcomes averted (MOAs), such as pelvic inflammatory disease (PID), ectopic pregnancy or infertility. Whilst most studies focussed on PID as an outcome measure, the study by Gift et al. looked at the number of chlamydia and gonorrhoea cases treated.[43] The reason for this was the inclusion of both men and women, and as PID is specific to women, MOAs would not be appropriate. The eight cost-utility analyses utilised QALYs as an outcome measure. Multiple studies (12) also applied other outcome measures, such as monetary outcomes or the number of patients cured.[31,50]

Perspective

Thirteen studies applied a healthcare and eleven a broader societal perspective. Whilst studies from the Netherlands and Sweden collected and analysed their data from a societal perspective, the economic evaluations from the UK were conducted from a narrower healthcare perspective. Two studies analysed their data from both a societal and provider perspective.[43,48] Five studies did not report their perspective.[29,36-38,42]

Study designs

The study design of the included studies were mostly model-based (30 studies). However, heterogeneity was found when looking at the range of model types applied. Out of the 30 studies, fourteen applied dynamic models, which are recommended for economic evaluations of infectious diseases,[23] while one study utilised a mixed approach of static and dynamic modelling[56] and the remainder exclusively applied static models (15 studies). One study

consisted of an economic evaluation only as it was based on a pilot cluster randomised controlled trial.[33]

Comparators

A range of screening interventions were considered, such as organised screening for chlamydia targeting a certain age group and/or setting, and they were generally compared to a no organised screening programme (16 studies). For three studies the comparator was not explicitly stated.[28,37,38]

Costing approaches and costs included

The cost data incorporated by the studies mostly used a bottom-up costing approach (22 studies). Nine studies chose a broad costing approach, which lists general programme costs but does not provide information on all costs per unit[34,37,38,40,42,46,50,52,57]. Overall, the studies focussed on direct medical costs, such as programme costs, which consisted of invites for screening and costs for testing and treatment. Eleven studies included indirect costs, which were mainly loss of productivity due to illness.

Time period

Out of the 31 studies, 29 did state a time period for their intervention and model calculations. Two studies did not provide clear information on the time period under consideration.[39,49] There was a variety in the time horizons applied ranging from a patient's lifetime to 2 years. Justification for the time periods varied and included the time onset of sequelae, such as PID, following an infection.

Sensitivity analysis

All studies, except for three, conducted some form of assessment of uncertainty.[27,29,57] The most common method applied was a univariate sensitivity analysis (26 studies) followed by multivariate sensitivity analysis (8 studies).[35,42,45-47,52-54] This involved the variation of selected parameters, such as MOAs including PID probability, the discount rate or the probability of screening uptake.

Table 2. Methodological specifications on economic evaluations of STI control programmes

Author (year)	*Type of economic evaluation*	*Outcome measure*			*Perspective (healthcare provider/ societal)*	*Study design (dynamic or static model/ trial)*	*Comparator*	*Costing approach and included costs*	*Data source for costs and outcomes*	*Time period and discount rate*	*Sensitivity analysis*
		QALY	*MOA*	*Other*							
Neilan (2018)	Cost-effectiveness analysis			✓	Healthcare provider	Dynamic model	Routine care	Broad approach; direct medical costs[1]	Secondary	Lifetime; 3%	✓
Owusu-Edusei (2016)	Cost-utility analysis	✓			Societal	Dynamic model	Risk-based screening (30% coverage)	Broad approach; direct medical costs and indirect costs[2]	Secondary	50 years; 3%	✓
de Wit (2015)	Cost-utility analysis	✓	✓		Societal	Static model	No organised screening	Bottom-up approach; programme costs, direct medical costs, indirect costs	Secondary	10 years; 4% costs and 1.5% effects	✓
Jackson (2015)	Cost-consequence analysis			✓	Healthcare provider	Trial	Two STI screening interventions	Bottom-up approach; direct medical costs and some private costs	Primary	NA; NA	✓
Teng (2015)	Cost-effectiveness analysis			✓	Societal cost-saving	Dynamic model	No organised screening	Broad approach; direct medical costs	Secondary	Depending on the age; No discount rate stated	X
Gillespie (2012)	Cost-utility analysis	✓	✓		Healthcare provider	Dynamic model	No organised screening	Bottom-up approach; direct medical costs	Primary and secondary	10 years; 3.5%	✓
Huang (2011)	Cost-effectiveness analysis		✓	✓	Healthcare provider	Static model	Routine care	Bottom-up approach; direct medical costs	Primary and secondary	10 years, 5 years, 2 years; 3%	✓
Turner (2011)	Cost-effectiveness analysis			✓	Healthcare provider	Static model	Base case data: NCSP (2008/9)	Broad approach; programme costs, direct medical costs	Primary	NA; NA	✓
de Vries (2008)	Cost-utility analysis	✓			Societal	Dynamic model	One-off screening	Bottom-up approach; direct and indirect medical costs; programme costs	Primary and secondary	20 years; 4%	X (previously applied in the 2006 study)
Gift (2008)	Cost-utility analysis	✓	✓		Societal	Dynamic model	Screening programme for women	Bottom-up approach; direct medical costs, programme costs, indirect costs	Primary and secondary	Model: 5 years, analytic horizon 20 years; 3%	✓
Adams (2007)	Cost-utility analysis	✓	✓		Healthcare provider	Dynamic model	No organised screening	Bottom-up approach; direct medical costs	Secondary	10 years; 3.5%	✓
Low (2007)	Cost-effectiveness analysis		✓		X	Dynamic model	No organised screening	Bottom-up approach; direct medical costs, programme costs	Primary and secondary	Around 20.5 years; 3.5%	✓
Andersen (2006)	Cost-effectiveness analysis		✓	✓	Societal and healthcare provider	Dynamic model	In-office screening	Bottom-up approach; direct medical costs, programme costs, indirect costs	Primary and secondary	10 years; 3%	✓
Bernstein (2006)	Cost-effectiveness analysis			✓	X	Static model	No organised screening	Broad approach; direct medical costs	Primary and secondary	10 years; 3%	✓
de Vries (2006)	Cost-effectiveness analysis		✓		Healthcare provider	Dynamic model	X	Bottom-up approach; direct and indirect medical costs; programme costs	Primary and secondary	10 years; 4%	✓
Evenden (2006)	Cost-effectiveness analysis			✓	X	Dynamic model	X	Broad approach; direct medical costs	Primary (expert opinion/trial) and secondary	2 years; No discount rate applied	✓
Walleser (2006)	Cost-utility analysis	✓			Healthcare provider	Static model	No organised screening	Bottom-up approach; direct medical costs	Secondary (expert opinion if no data)	25 years; 5%	✓
Aledort (2005)	Cost-utility analysis	✓	✓	✓	Societal	Static model	Routine care	Bottom-up approach; direct medical costs	Secondary	A woman's lifetime; 3%	✓
Evenden (2005)	Cost-benefit analysis/ cost-effectiveness analysis			✓	X	Dynamic model	X	Broad approach; direct medical costs	Secondary (expert opinion)	2 years; No discount rate applied	✓

Table 2. Methodological specifications on economic evaluations of STI control programmes

Author (year)	*Type of economic evaluation*	*Outcome measure*			*Perspective (healthcare provider/ societal)*	*Study design (dynamic or static model/ trial)*	*Comparator*	*Costing approach and included costs*	*Data source for costs and outcomes*	*Time period and discount rate*	*Sensitivity analysis*
		QALY	*MOA*	*Other*							
Gift (2005)	Cost-effectiveness analysis			✓	Healthcare provider & societal	Static model	Baseline intervention 1 and 4	Bottom-up approach; counselling costs, direct medical costs, and indirect costs	Primary and secondary	10 years; 3%	✓
Hu (2004)	Cost-effectiveness analysis		✓	✓	Modified societal	Static and dynamic model	No organised screening	Bottom-up approach; direct medical costs	Secondary	Lifetime; discounting applied, rate not stated	✓
Norman (2004)	Cost-effectiveness analysis		✓	✓	Healthcare provider	Static model	No organised screening	Bottom-up approach; direct medical costs	Primary and secondary	No time period stated; 5% and 3%	✓
Novak (2004)	Cost-effectiveness analysis		✓		Societal	Static model	No organised screening	Bottom-up approach; direct medical costs	Primary and secondary	No time period or discount rate stated	✓
Tao (2004)	Cost-consequence analysis		✓	✓	Healthcare provider	Static model	Different screening strategies	Broad approach; direct medical costs	Secondary	NA; NA	✓
van Bergen (2004)	Cost-effectiveness analysis		✓		X	Static model	No organised screening	Bottom-up approach; direct medical costs, indirect costs	Primary and secondary	Programme evaluation after 2 years; 4%	X
Gift (2002)	Cost-effectiveness analysis		✓		Healthcare provider	Static model	Different screening strategies	Bottom-up approach; direct medical costs	Secondary	Patient's lifetime; 3%	✓
Mehta (2002)	Cost-effectiveness analysis			✓	Healthcare provider	Static model	Routine care	Bottom-up approach; direct medical costs, programme costs	Primary and secondary	10 years; 3%	✓
van Valkengoed (2001)	Cost-effectiveness analysis		✓		Societal	Static model	No organised screening	Bottom-up approach; direct medical costs, programme costs, indirect costs	Primary and secondary	5 years; 3%	✓
Postma (2000)	Cost-effectiveness analysis		✓	✓	Societal	Static model	No organised screening	Bottom-up approach; direct medical costs, indirect costs	Primary and secondary	5 years, 10 years; 3%	✓
Townshend (2000)	Cost-effectiveness analysis		✓	✓	Healthcare provider	Dynamic model	No organised screening	Broad approach; direct medical costs	Secondary	10 years for costs and 40 years for MOs; 6%	✓
Welte (2000)	Cost-effectiveness analysis		✓		Societal	Dynamic model	No organised screening	Bottom-up approach; direct medical costs, indirect costs	Secondary	20 years; 3%	✓

✓=Done, ✓/X = To some extent completed, X=Not reported; NA = Not applicable

[1]Direct medical costs: Costs for testing (including clinician time), treatment (including the cost of a return visit), and sequelae costs, such as PID

[2]Indirect costs refer to cost of lost productivity due to illness

CT=*Chlamydia trachomatis*; MO=Major outcome; MOA=Major outcome averted; NA=Not applicable; NCSP=National Chlamydia Screening Programme; PID=Pelvic inflammatory disease; PN=Partner notification; QALY=Quality-adjusted life year

Critical appraisal of studies

All economic evaluations were subject to a critical assessment as a measure of study quality using one checklist for economic models and one for other economic evaluations (see Supplement 4 and Supplement 5).[24,25] In general, the modelling studies frequently neglected to argue for the scope and perspective of the study. Studies were also unclear in reporting their modelling types, which made it challenging to classify some economic evaluations.[38,50] The uncertainties associated with model structures were often not completely assessed. Most studies did review parameter uncertainty in the form of a univariate analysis or probabilistic sensitivity analysis. However, they neglected methodological uncertainty, i.e. running alternative versions of the model with different methodological assumptions, as well as sub-group analysis making the reliability of model results uncertain. The study by Jackson et al. did fulfil most of the BMJ checklist criteria except for stating the research question and for explaining the choice of the study type in relation to the research question.[33]

DISCUSSION

This systematic review identified 31 economic evaluations of control programmes for STIs and HIV targeting young people. In general, the studies applied a cost-effectiveness or cost-utility analysis for interventions that mainly focussed on chlamydia screening. The results show that there was a great variety in the approaches adopted to evaluate the control programmes for STIs/HIV. This comprises the overall heterogeneity in methods including measurement of outcomes and differences in the perspectives applied. The studies were also of variable quality.

One might expect that over a twenty-year period, there would be more convergence among the studies to allow better comparability and understanding of the overall results, such as whether, overall, the intervention was cost-effective or not. However, due to the large variance in methods applied along with the low quality of models, it is difficult to draw a final conclusion from most of the studies. Static models, among other aspects, do not take interdependences of individuals into account and therefore jeopardise the interpretation of the model results. The studies reviewed applied a mix of static and dynamic models (14 out of 30 were dynamic models) and there was no evidence that since the review by Roberts et al. in 2006[58], which highlighted the importance of dynamic modelling for infectious diseases, that more dynamic models are being used. It was noted, however, that when a dynamic model was not used, authors acknowledged the limitations of this.

The evaluations did not consider equity of service provision for individuals nor the intervention's context, which are vital for local decision-makers in public health. In order to enable outcomes beyond health to be considered, a broader perspective for economic evaluation would be required. This was not the case for several studies despite the recommendation by NICE in 2012 for performing economic evaluations of public health interventions.[7]

Further, only two studies focussed their economic evaluation on the newer modes of delivery for screening, such as online services and services provided in community settings.[29,47] However, it was acknowledged by some authors that their economic models were limited in this respect.[30]

To compare different types of economic evaluations is challenging since the differences in methodology result in different outcome measures, including intermediate (MOAs) and long-term (QALYs) outcomes. Several studies highlighted that due to the lack of data about the risk of clinical progression following acute gonorrhoea infection and its impact on quality of life, they were unable to calculate QALYs.[41,42] In addition, even if utility data was available, it was still challenging to calculate QALYs due to the low quality of the data.[33] The overall lack of data on sexual behaviour and transmission patterns[32,48] along with a lack of clarity for one of the most influential parameters affecting cost-effectiveness (PID probability – which is estimated to range anywhere from 10% - 40%[26,44,45,48,54]) intensified uncertainty in interpreting study results.

The quality assessment of the studies showed that a significant number did not fulfil all the requirements for an economic evaluation,[24] and this was particularly the case for uncertainty assessment. Most of the authors did not justify why they omitted certain steps in assessing uncertainty and rarely was subgroup analysis conducted to understand the differential costs and effects on certain vulnerable population groups, which is an important aspect since resources may be wasted and opportunities for a specific sub-group may be lost.[23]

Comparison with other literature

Our findings update and confirm those from previous systematic reviews in this area. The predominant utilisation of cost-effectiveness analyses with static models to evaluate costs and outcomes of screening and testing for STIs and HIV has been highlighted previously.[11,58] Despite this, methodological issues seem to persist, which may be explained partially by a lack of suitable data to include within analyses.[33]

Policy implications

The results of this systematic review show that current economic evidence has limitations, which may impact on its interpretation and use in policy decision-making. The important focus of public health interventions on equity in addition to health improvement, as well as the context within which they are delivered, indicates that future economic evaluations also need to address these multiple domains.

Strengths and weaknesses of this review

This review has several strengths. A robust methodology incorporating a thorough search strategy across multiple databases along with article hand searching was applied. Further, it focusses on young people who are particularly vulnerable with regard to STIs. One weakness of the review is that by focussing on young people, other vulnerable groups, such as men who have sex with men or minority ethnic groups, may have been omitted and additional important economic evaluations specific to these groups may have been missed. Applying different inclusion and categorisation criteria may yield further future insights into economic evaluations for these groups.

Further research

There is a tension between following recommendations for conducting an economic evaluation for a public health programme and ensuring real world applicability, for example utilising QALYs for comparability vs. the needs of local decision-making. Future research needs to address these tensions with the aim to improve knowledge translation between health economists and public health decision-makers and ensure the wider applicability of health economic findings.

CONCLUSION

This review has highlighted some limitations in existing economic evaluations which focus on STI and HIV control programmes, particularly in terms of context, equity, an appopriate time horizon, and wider costs and benefits beyond health. It has illustrated wide heterogeneity in the published economic evaluations of STI and HIV control programmes and this, combined with limited study quality, demonstrates a need for further economic evaluations, which can directly inform improvements in patient care.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

KEY MESSAGES

- This systematic review identifies and assesses economic evaluations of control programmes for sexually transmitted infections and HIV targeting young people.
- The economic evaluations found had limitations in terms of measuring costs and benefits beyond health and considering aspects of context and equity, which are of particular importance to local public health decision-makers.
- There is a need for further high quality economic evaluations, which can directly inform improvements in sexual health services.

LEGEND

Figure 1. PRISMA flow-diagram of study categorisation stages I and II.

Stage I categorisation: A) Economic evaluation of a STI/HIV control programme targeting young people, containing primary or secondary data on both costs and outcomes; B) Contains original data (primary research) on the cost and/or economic outcomes of STI/HIV control programmes of the target population, e.g. QALY, DALY etc.; C) Incomplete economic evaluation; D) Focus on other STIs; E) Target population was not young people; F) Economic evaluation of diagnostic test; G) Systematic review; H) Unclear; I) No relevance;

Stage II categorisation: 1) Complete economic evaluation; 2) Study presents an economic evaluation; 3) Different methods for an economic evaluation are described; 4) Review of economic features of control programmes for STIs/HIV; 5) No relevance; (see Supplement 3)

DALY, Disability-adjusted life years; DARE, Database of Abstracts of Reviews of Effects; HTA, Health Technology Assessment; NHS EED, NHS Economic Evaluation Database; NICE, National Institute for Health and Care Excellence; QALY, Quality-adjusted life years; STI, Sexually transmitted infection

REFERENCES

1 Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: A systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. *BMC Public Health* 2013;13:1–13. doi:10.1186/1471-2458-13-1001

2 Payne L, McAllister K, Davies M. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. *Health Econ* 2013;22:258–71. doi:10.1002/hec

3 Marsh K, Phillips CJ, Fordham R, et al. Estimating cost-effectiveness in public health: A summary of modelling and valuation methods. *Health Econ Rev* 2012;2:1–6. doi:10.1186/2191-1991-2-17

4 Lorgelly PK, Lawson KD, Fenwick EAL, et al. Outcome measurement in economic evaluations of public health interventions: A role for the capability approach? *Int J Environ Res Public Health* 2010;7:2274–89. doi:10.3390/ijerph7052274

5 Weatherly H, Drummond M, Claxton K, et al. Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations. *Health Policy (New York)* 2009;93:85–92. doi:10.1016/j.healthpol.2009.07.012

6 National Institute for Health and Care Excellence (NICE). Developing NICE Guidelines: the manual. 2014;:1–237.https://www.nice.org.uk/process/pmg20 (accessed 9 Nov 2020).

7 National Institute for Health and Care Excellence (NICE). Methods for the development of NICE public health guidance (third edition). 2012. https://www.nice.org.uk/process/pmg4/chapter/introduction (accessed 13 May 2020).

8 Williams I, Bryan S. Lonely at the top and stuck in the middle? The ongoing challenge of using cost-effectiveness information in priority setting. *Int J Heal Policy Manag* 2015;4:185–7. doi:10.15171/ijhpm.2015.32

9 Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. *Heal Econ Policy Law* 2009;4:231–45. doi:10.1017/S1744133109004903

10 Steen R, Elvira Wi T, Kamali A, et al. Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm. *Bull World Health Organ* 2009;87:858–65. doi:10.2471/BLT.08.059212

11 Jackson LJ, Auguste P, Low N, et al. Valuing the health states associated with chlamydia trachomatis infections and their sequelae: A systematic review of economic evaluations and primary studies. *Value Heal* 2014;17:116–30. doi:10.1016/j.jval.2013.10.005

12 Shepherd J, Kavanagh J, Picot J, et al. The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19 years: a systematic review and economic evaluation. *Health Technol Assess (Rockv)* 2010;14:1–230. doi:10.1093/her/cys014

13 Bailey J, Mann S, Wayal S, et al. Sexual health promotion for young people delivered via digital media: a scoping review. *Public Heal Res* 2015;3. doi:10.3310/phr03130

14 Public Health England. Making it work: A guide to whole system commissioning for sexual health, reproductive health and HIV. London: 2014. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/408357/Making_it_work_revised_March_2015.pdf (accessed 10 Dec 2018).

15 Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009;6:e1000097. doi:10.1371/journal.pmed.1000097

16 Centre for Reviews and Dissemination, University of York. *Systematic Reviews: CRD's guidance for undertaking reviews in health care*. York: Centre for Reviews and Dissemination, University of York 2009. doi:10.1103/PhysRev.143.275

17 European Centre for Disease Prevention and Control. European Network for STI Surveillance. 2020.https://www.ecdc.europa.eu/en/about-uswho-we-workdisease-and-laboratory-networks/european-network-sti-surveillance (accessed 23 Apr 2020).

18 European Centre for Disease Prevention and Control. European Network for HIV/AIDS Surveillance. 2020.https://www.ecdc.europa.eu/en/about-uswho-we-workdisease-and-laboratory-networks/european-network-hivaids-surveillance (accessed 23 Apr 2020).

19 National Institute for Health and Care Excellence (NICE). Who we are. 2019.https://www.nice.org.uk/about/who-we-are (accessed 19 Mar 2019).

20 Rawlins MD. National Institute for Clinical Excellence: NICE works. *J R Soc Med* 2015;108:211–9. doi:10.1177/0141076815587658

21 Clarivate Analytics. EndNote. 2019.https://endnote.com/ (accessed 16 May 2019).

22 Roberts T, Henderson J, Mugford M, et al. Antenatal ultrasound screening for fetal abnormalities: A systematic review of studies of cost and cost effectiveness. *BJOG An Int J Obstet Gynaecol* 2002;109:44–56. doi:10.1111/j.1471-0528.2002.00223.x

23 Drummond MF, Sculpher MJ, Claxton K, et al. *Methods for the Economic Evaluation of Health Care Programmes*. 4th ed. Oxford: Oxford University Press 2015.

24 Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. *BMJ* 1996;313:275–83. doi:10.1136/bmj.313.7052.275

25 Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. *Health Technol Assess (Rockv)* 2004;8. doi:10.3310/hta8360

26 de Wit GA, Over EAB, Schmid B V, et al. Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands. *Sex Transm Infect* 2015;91:423–9. doi:https://dx.doi.org/10.1136/sextrans-2014-051677

27 de Vries R, van Bergen JEAM, de Jong-van den Berg LTW, et al. Cost-utility of repeated screening for Chlamydia trachomatis. *Value Health* 2008;11:272–4. doi:https://dx.doi.org/10.1111/j.1524-4733.2007.00225.x

28 de Vries R, van Bergen JEAM, de Jong-van den Berg LTW, et al. Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. *Value Heal* 2006;9:1–11.

29 van Bergen JEAM, Postma MJ, Peerbooms PGH, et al. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples. *Int J STD AIDS* 2004;15:797–802.

30 van Valkengoed IG, Postma MJ, Morre SA, et al. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. *Sex Transm Infect* 2001;77:276–82.

31 Postma M, Welte R, Hoek A Van Den, et al. Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis: The importance of reinfection and partner referral. *Heal Econ Prev Care* 2000;1:103–10.

32 Welte R, Kretzschmar M, Leidl R, et al. Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. *Sex Transm Dis* 2000;27:518–29.

33 Jackson LJ, Roberts TE, Fuller SS, et al. Exploring the costs and outcomes of sexually transmitted infection (STI) screening interventions targeting men in football club settings: preliminary cost-consequence analysis of the SPORTSMART pilot randomised controlled trial. *Sex Transm Infect* 2015;91:100–5. doi:10.1136/sextrans-2014-051715

34 Turner K, Adams E, Grant A, et al. Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study. *BMJ* 2011;342:c7250. doi:https://dx.doi.org/10.1136/bmj.c7250

35 Adams EJ, Turner KME, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. *Sex Transm Infect* 2007;83:267–74. doi:10.1136/sti.2006.024364

36 Low N, McCarthy A, Macleod J, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. *Health Technol Assess (Rockv)* 2007;11.

37 Evenden D, Harper PR, Brailsford SC, et al. Improving the cost-effectiveness of Chlamydia screening with targeted screening strategies. *J Oper Res Soc* 2006;57:1400–12. doi:10.1057/palgrave.jors.2602134

38 Evenden D, Harper PR, Brailsford SC, et al. System Dynamics modelling of Chlamydia infection for screening intervention planning and cost-benefit estimation. *IMA J Manag Math* 2005;16:265–79. doi:10.1093/imaman/dpi022

39 Norman JE, Wu O, Twaddle S, et al. An evaluation of economics and acceptability of screening for Chlamydia trachomatis infection, in women attending antenatal, abortion, colposcopy and family planning clinics in Scotland, UK. *BJOG An Int J Obstet Gynaecol* 2004;111:1261–8. doi:10.1111/j.1471-0528.2004.00324.x

40 Townshend JRP, Turner HS. Analysing the effectiveness of Chlamydia screening. *J Oper Res Soc* 2000;51:812–24. doi:10.2307/253962

41 Aledort JE, Hook EW 3rd, Weinstein MC, et al. The cost effectiveness of gonorrhea screening in urban emergency departments. *Sex Transm Dis* 2005;32:425–36.

42 Bernstein KT, Mehta SD, Rompalo AM, et al. Cost-effectiveness of screening

strategies for Gonorrhea among females in private sector care. *Obstet Gynecol* 2006;107:813–21. doi:10.1097/01.AOG.0000204187.86600.0a

43 Gift TL, Malotte CK, Ledsky R, et al. A cost-effectiveness analysis of interventions to increase repeat testing in patients treated for gonorrhea or chlamydia at public sexually transmitted disease clinics. *Sex Transm Dis* 2005;32:542–9. doi:10.1097/01.olq.0000175414.80023.59

44 Gift T, Walsh C, Haddix A, et al. A cost-effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. *Sex Transm Dis* 2002;29:542–51.

45 Mehta SD, Bishai D, Howell MR, et al. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. *Sex Transm Dis* 2002;29:83–91.

46 Neilan AM, Dunville R, Ocfemia MCB, et al. The optimal age for screening adolescents and young adults without identified risk factors for HIV. *J Adolesc Heal* 2018;62:22–8. doi:10.1016/j.jadohealth.2017.08.028

47 Huang W, Gaydos CA, Barnes MR, et al. Cost-effectiveness analysis of Chlamydia trachomatis screening via internet-based self-collected swabs compared with clinic-based sample collection. *Sex Transm Dis* 2011;38:815–20. doi:10.1097/OLQ.0b013e31821b0f50

48 Andersen B, Gundgaard J, Kretzschmar M, et al. Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis Infections. *Sex Transm Dis* 2006;33:407–15. doi:10.1097/01.olq.0000200609.77577.3f

49 Novak DP, Lindholm L, Jonsson M, et al. A Swedish cost-effectiveness analysis of community-based Chlamydia trachomatis PCR testing of postal urine specimens obtained at home. *Scand J Public Health* 2004;32:324–32.

50 Tao G, Abban BK, Gift TL, et al. Applying a mixed-integer program to model re-screening women who test positive for C. trachomatis infection. *Health Care Manag Sci* 2004;7:135–44.

51 Gillespie P, O'Neill C, Adams E, et al. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland. *Sex Transm Infect* 2012;88:222–8. doi:https://dx.doi.org/10.1136/sextrans-2011-050067

52 Owusu-Edusei K, Hoover KW, Gift TL. Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the US. *Am J Prev Med* 2016;51:216–24. doi:10.1016/j.amepre.2016.01.007

53 Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. *Sex Transm Dis* 2008;35:S66-75. doi:10.1097/OLQ.0b013e31818b64ac

54 Walleser S, Salkeld G, Donovan B. The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia. *Sex Health* 2006;3:225. doi:10.1071/SH06016

55 Drummond M, Sculpher M, Torrance G, et al. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford: Oxford University Press 2005.

56 Hu D, Hook EW 3rd, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. *Ann Intern Med* 2004;141:501–13.

57 Teng Y, Kong N, Tu W. Optimizing strategies for population-based chlamydia infection screening among young women: An age-structured system dynamics approach. *BMC Public Health* 2015;15. doi:10.1186/s12889-015-1975-z

58 Roberts TE, Robinson S, Barton P, et al. Screening for Chlamydia trachomatis: A systematic review of the economic evaluations and modelling. *Sex Transm Infect* 2006;82:193–200. doi:http://dx.doi.org/10.1136/sti.2005.017517



Figure 1. PRISMA flow-diagram of study categorisation stages I and II.
Stage I categorisation: A) Economic evaluation of a STI/HIV control programme targeting young people, containing primary or secondary data on both costs and outcomes; B) Contains original data (primary research) on the cost and/or economic outcomes of STI/HIV control programmes of the target population, e.g. QALY, DALY etc.; C) Incomplete economic evaluation; D) Focus on other STIs; E) Target population was not young people; F) Economic evaluation of diagnostic test; G) Systematic review; H) Unclear; I) No relevance;
Stage II categorisation: 1) Complete economic evaluation; 2) Study presents an economic evaluation; 3) Different methods for an economic evaluation are described; 4) Review of economic features of control programmes for STIs/HIV; 5) No relevance; (see Supplement 3)
DALY, Disability-adjusted life years; DARE, Database of Abstracts of Reviews of Effects; HTA, Health Technology Assessment; NHS EED, NHS Economic Evaluation Database; NICE, National Institute for Health and Care Excellence; QALY, Quality-adjusted life years; STI, Sexually transmitted infection

140x150mm (120 x 120 DPI)

Supplement 1. MEDLINE search strategy

Medline was searched using the Ovid interface on 20 March 2019 for the period 1946 to March Week 3 2019.

1	sexually transmitted diseases/ or *sexually transmitted diseases, bacterial/ or STDs.mp. or sexually transmitted infections.mp. or STIs.mp. or sexually transmissible disease.mp. or sexually transmissible infection.mp. or sexually transmitted disorder.mp. or sexually transmissible disorder.mp. (31,588)
2	chlamydia.mp. or exp Chlamydia/ or chlamydia infections.mp. (28,331)
3	gonorrh?ea.mp. or exp Gonorrhea/ or neisseria gonorrhoeae.mp. (23,504)
4	syphilis.mp. or exp Syphilis/ or treponema pallidum.mp. (37,116)
5	human immunodeficiency virus.mp. or exp Human Immunodeficiency Virus/ or HIV.mp. (342,150)
6	1 or 2 or 3 or 4 or 5 (428,119)
7	exp "costs and cost analysis"/ or exp Health Care Costs/ (222,777)
8	exp Cost Benefit Analysis/ (75,712)
9	quality-adjusted life year$.ti,ab,kw. or exp Quality-Adjusted Life Years/ (15,722)
10	(cost$ adj2 (effective$ or utilit$ or benefit$ or consequence$ or minimi$)).ti,ab,kw. (140,559)
11	(decision adj (analy$ or model$ or tree$)).ti,ab,kw. (15,159)
12	economic evaluation$.ti,ab,kw. (10,744)
13	7 or 8 or 9 or 10 or 11 or 12 (326,148)
14	public health.mp. or Public Health/ (281,942)
15	screen$.ti,ab,kw. (661,235)
16	diagnostic tests.ti,ab,kw. or Diagnostic Tests, Routine/ (30,135)
17	Mass screening.ti,ab,kw. (5,707)
18	diagnosis.ti,ab,kw. or Diagnosis/ (1,379,040)
19	14 or 15 or 16 or 17 or 18 (2,230,991)
20	6 and 13 and 19 (2,977)
21	limit 20 to humans (2,721)
22	limit 21 to yr="1999 -Current" (2,113)

Supplement 2. List of data extraction categories

1 Lead author, year
2 Country
3 Sample size, patient population
4 Demographics (ethnicity, age, area, spectrum of risk)
5 Evaluation aims
6 Prevalence of infection
7 Reported risk level (high, medium, low)
8 Intervention focus (testing, screening)
9 Infections included (chlamydia, gonorrhoea, syphilis, HIV)
10 Outcomes (life-years gained, QALY, MOA, monetary outcome, other)
11 Perspective
12 Type of economic evaluation
13 Model/trial based
14 Time period
15 Comparator
16 Costs included
17 Discounting/year
18 Primary/secondary data
19 Information presented about the outcomes (literature, trial/intervention, clinic/patient database)
20 Information presented about the costs (literature, trial/intervention, clinic/patient database)
21 Costing approach (bottom up, broad)
22 Sensitivity analysis (univariate, threshold, multivariate, scenario / probabilistic)
23 Results
24 Funder of intervention
25 Limitations

Supplement 3. Categorisation Stages I and II

Box 1: Stage I categories

A. The study presents an economic evaluation of a STI/HIV control programme targeting young people and therefore contains useful primary or secondary data on both costs and outcomes of the assessed intervention;

B. The study shows original data (primary research) on the cost and/or economic outcomes of STI/HIV control programmes of the target population (where economic outcomes are defined as QALY, DALY, HALY, monetised benefits, capabilities,?);

C. The study may have useful information, i.e. economic characteristics, targets young people but does not clearly belong to either category (A) or (B);

D. The study focuses on economic evaluations of control programmes for less prevalent STIs, i.e. genital warts or trichomonas vaginalis targeting young people or other risk groups, i.e. MSM without age specification;

E. The economic evaluation of STI/HIV testing and screening has no particular focus on young people, i.e. general population focus or other risk groups including methods of partner notification and prenatal testing;

F. The study presents an economic evaluation of tests and diagnostic tools for STIs/HIV;

G. The study is a systematic review of an economic evaluation of a STI/HIV control programme targeting young people;

H. Based on title/abstract/keywords it is not clear whether the study may contain useful information of economic evaluations of STI/HIV control programmes targeting young people;

I. No relevance to economic evaluations of STI/HIV control programmes targeting young people.

Box 2: Stage II categories

1. Complete economic evaluation, i.e. cost-effectiveness analysis or cost-utility analysis of a STI control programme targeting young people;

2. Incomplete or partial economic evaluation of control programmes for STIs/HIV including ongoing studies and studies focusing on measuring the economic burden and/or resource use;

3. A study describing different methods for an economic evaluation of control programmes for STIs/HIV;

4. Review of economic features of control programmes for STIs, i.e. a secondary study which includes some kind of overview of costs or resource use of a STI/HIV control programme;

5. No relevance for economic evaluations of sexual health programmes.

Supplement 4. Critical appraisal of modelling studies using Philips checklist (Philips et al., 2004)[24]

Table 3. Critical appraisal of modelling studies

Author (year)	*Structure 1-3 (statement of decision, problem, objective; scope/perspective; rationale)*	*Structure 4-6 (assumptions;comparators; model type)*	*Structure 7 (time horizon)*	*Structure 8 (disease pathways)*	*Structure 9 (cycle length)*	*Data 1 (identification)*	*Data 2 & 2a (data modelling;baseline data justified)*	*Data 2b, 2c, 2d (treatment effects; costs justified; QoL weigths)*	*Data 3 (incorporation)*	*Data 4 (uncertainty assessment)*	*Data 4a-4d (methodological; structural; heterogeneity; parameter)*	*Consistency 1 & 2 (internal & external)*
Neilan (2018)	✓,✓,X	✓,✓,X	✓	✓	X	✓/X	X/✓,✓	✓,X,NA	X	✓	X,✓,✓,✓	X, ✓
Owusu-Edusei (2016)	✓,✓,✓	✓,✓,✓	✓	✓	X	✓	✓,✓	✓,✓,✓	✓	✓	X,✓,✓,✓	✓,✓
de Wit (2015)	✓,✓,✓	✓,✓,✓	✓/X	✓	X	✓	✓,✓	✓,✓,✓/X	✓	✓	X,✓,✓,✓	✓,✓
Teng (2015)	✓,✓,✓	✓,✓,✓	✓/X	✓/X	X	X	✓,X	✓	✓/X	X	X,X,X,X	X,NA
Gillespie (2012)	✓,✓,✓	✓,✓,✓	✓	NA	X	✓	✓,✓	NA,✓,X	✓	✓	X,X,X,✓	✓,X
Huang (2011)	✓,✓/X,✓/X	✓,✓,X	✓	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,✓,X,✓	X,X
Turner (2011)	✓,✓,X	✓,✓,✓	NA	NA	NA	✓	✓,✓	✓,✓,NA	✓	✓	X,✓,X,✓	✓,✓
de Vries (2008)	✓,✓/X,✓	✓,✓,✓	✓	✓	X	✓	✓/X,✓	✓/X,✓,✓	✓	✓/X	X,X,X,X	X,X
Gift (2008)	✓,✓/X,✓	✓,✓,✓/X	✓	✓	X	✓	✓,✓	✓/X,✓,✓	✓	✓	X,✓,✓,✓	X,X
Adams (2007)	✓,✓/X,✓/X	✓,✓,✓/X	✓/X	✓	X	✓/X	✓,✓/X	✓/X,X,X	✓/X	✓	X,✓,✓,✓	X,✓
Low (2007)	✓,X,✓	✓,✓,✓	✓	✓/X	X	✓	✓,✓	✓,✓,NA	✓	✓	X,✓,X,✓	X,✓
Andersen (2006)	✓,✓/X,✓	✓,✓,✓	✓/X	✓	X	✓	✓,✓	✓/X,✓,NA	✓	✓	X,X,✓,✓	X,X
Bernstein (2006)	✓,✓/X,✓	✓,✓,✓	✓/X	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,X,✓,✓	X,NA
de Vries (2006)	✓,✓/X,✓	✓,X,✓	✓	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,X,✓,✓	X,X
Evenden (2006)	✓,X,✓	X,✓,✓	✓/X	✓	X	✓/X	✓,X	✓/X,X,NA	✓/X	✓	X,X,✓,✓	X,X
Walleser (2006)	✓,✓,✓	✓,✓,✓	✓/X	✓	✓	✓	✓,✓	✓,✓,✓	✓	✓	X,X,X,✓	X,NA
Aledort (2005)	✓,✓/X,✓	✓,✓,X	✓/X	✓	✓	✓	✓,✓	✓,✓,✓/X	✓	✓	X,X,✓,✓	X,X
Evenden (2005)	✓,X,✓	✓,✓,✓	✓/X	✓	X	✓/X	✓,✓	✓/X,X,NA	X/✓	✓	X,X,✓,✓	X,X
Gift (2005)	✓,✓/X,✓	✓,✓,✓	✓	✓	X	✓	✓/X,✓	✓,✓,NA	✓	✓	X,✓,X,✓	X,X
Hu (2004)	✓,✓/X,✓/X	✓,✓,X	✓	✓	✓	✓	✓,X	✓/X,✓,✓	✓	✓	X,✓,X,✓	X,✓

Table 3. Critical appraisal of modelling studies

Author (year)	*Structure 1-3 (statement of decision, problem, objective; scope/ perspective; rationale)*	*Structure 4-6 (assumptions;comparators; model type)*	*Structure 7 (time horizon)*	*Structure 8 (disease pathways)*	*Structure 9 (cycle length)*	*Data 1 (identification)*	*Data 2 & 2a (data modelling;baseline data justified)*	*Data 2b, 2c, 2d (treatment effects; costs justified; QoL weigths)*	*Data 3 (incorporation)*	*Data 4 (uncertainty assessment)*	*Data 4a-4d (methodological; structural; heterogeneity; parameter)*	*Consistency 1 & 2 (internal & external)*
Norman (2004)	✓,✓,X	X,✓,X	X	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,X,✓,✓	X,✓
Novak (2004)	✓,✓,X	✓,✓,X	X	✓	X	✓	X,✓	✓,✓,NA	✓	✓	X,X,X,✓	X,NA
Tao (2004)	✓,✓,✓	✓,✓,✓	✓/X	✓	X	✓	✓,X	✓/X,✓,NA	✓	✓	X,X,✓,✓	X,X
van Bergen (2004)	✓,✓,✓	✓,✓,✓	✓/X	✓	X	✓	✓,✓	✓,✓,NA	✓	X	X,X,✓,✓/X	X,✓
Gift (2002)	✓,✓,✓/X	✓,✓,✓/X	✓	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,✓,X,✓	X,X
Mehta (2002)	✓,✓,✓/X	✓,✓,X	✓/X	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,✓,X,✓	✓,NA
van Valkengoed (2001)	✓,✓,✓	✓,✓,✓	✓	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,✓,✓,✓	X,NA
Postma (2000)	✓,✓/X,✓	✓,✓,✓/X	✓	✓	X	✓	✓,✓	✓,✓,NA	✓	✓	X,X,✓,✓	X,✓
Townshend (2000)	✓,✓,✓	✓,✓/X,✓	✓	✓	X	✓	✓,X	✓,✓,NA	✓	✓	X,X,✓,✓	X,X
Welte (2000)	✓,✓,✓	✓,✓,✓	✓/X	✓	X	✓	✓,✓	✓,✓,X	✓	✓	X,✓,✓,✓	X,X

✓=Done, ✓/X = To some extent completed, X=Not reported; NA = Not applicable

Supplement 5. Critical appraisal of trial based studies using the BMJ checklist (Drummond and Jefferson, 1996)[23]

Table 4. Critical appraisal of trial based studies. Complete checklist (1/3)

	Study design (includes sections 1 to 3 from in text table)							*Data collection (includes sections 4 to 7 from in text table)*				
Author (year)	*(1) Research question stated*	*(2) Economic importance of research question stated*	*(3) Viewpoints of analysis stated & justified*	*(4) Rationale for choosing alternative programmes compared stated*	*(5) Alternatives being compared described*	*(6) Form of economic evaluation used stated*	*(7) Choice of economic evaluation form justified in relation to the question addressed*	*(8) Sources of effectiveness estimates used stated*	*(9) Details of design & results of effectiveness study given (single study)*	*(10) Details of synthesis method/ meta-analysis given (multiple studies)*	*(11) Primary outcome measures stated*	*(12) Methods to value health states & benefits are stated*
Jackson (2015)	X (aim stated)	X	✓	✓/X	✓	✓	✓/X	✓	✓	NA	✓	NA

✓=Done, ✓/X = To some extent completed, X=Not reported; NA = Not applicable

Table 4. Critical appraisal of trial based studies. Complete checklist cont. (2/3)

	Data collection (includes sections 4 to 7 from in text table)									*Analysis and interpretation of results (includes sections 8 to 10 from in text table)*		
Author (year)	*(13) Details of the subjects from whom valuations were obtained given*	*(14) Productivity changes (if included) reported separately*	*(15) Relevance of productivity changes to RQ discussed*	*(16) Quantities of resources separate from their unit costs*	*(17) Methods for estimation of quantities & unit costs described*	*(18) Currency & price data are recorded*	*(19) Details of currency/price adjustments for inflation/currency conversion given*	*(20) Details of any model used given*	*(21) Model choice & key parameters on which it is based justified*	*(22) Time horizon of costs & benefits stated*	*(23) Discount rate stated*	*(24) Choice of rate justified*
Jackson (2015)	NA	NA (done in SA)	✓	✓	✓	✓ (UK £ 2012/2013)	NA (intervention less than 1 year)	✓	✓	NA	NA	NA

✓=Done, ✓/X = To some extent completed, X=Not reported; NA = Not applicable

Table 4. Critical appraisal of trial based studies. Complete checklist cont. (3/3)

	Analysis and interpretation of results (includes sections 8 to 10 from in text table)										
Author (year)	*(25) Explanation if costs/ benefits not discounted*	*(26) Details of statistical tests & confidence intervals given for stochastic data*	*(27) Sensitivity analysis approach given*	*(28) Choice of variables for sensitivity analysis justified*	*(29) Ranges over which variables are varied stated*	*(30) Relevant alternatives compared*	*(31) Incremental analysis reported*	*(32) Major outcomes presented in a disaggregated & aggregated form*	*(33) Answer to research question given*	*(34) Conclusions follow from data reported*	*(35) Conclusions are accompanied by appropriate caveats*
Jackson (2015)	NA	NA	✓	✓/X	✓	✓	NA	✓	✓	✓	✓

✓=Done, ✓/X = To some extent completed, X=Not reported; NA = Not applicable